+ New Watchlist

Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Blueprint Medicines

BPMCNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$90.14

1.211.36%

At close: -

$90.00

-0.14-0.16%

After Hours: Dec 20, 4:55 PM EDT

Blueprint Medicines (BPMC) Forecast

News

Earnings Blueprint Medicines (BPMC) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Blueprint Medicines (NASDAQ:BPMC) Stock

Blueprint Medicines Stock (NASDAQ: BPMC)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, December 11, 2024

Guggenheim Reiterates Buy on Blueprint Medici...
Benzinga Newsdesk

Monday, December 09, 2024

JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Reported Saturday, Blueprint Medicines Showca...
Benzinga Newsdesk

Monday, November 18, 2024

JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk

Friday, November 15, 2024

HC Wainwright & Co. Reiterates Buy on Bluepri...
Benzinga Newsdesk
Needham Reiterates Buy on Blueprint Medicines...
Benzinga Newsdesk

Thursday, November 14, 2024

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
Vandana Singh
Key Takeaways From Blueprint Medicines Analyst Ratings
Benzinga Insights
JP Morgan Initiates Coverage On Blueprint Med...
Benzinga Newsdesk

Thursday, October 31, 2024

Wells Fargo Maintains Overweight on Blueprint...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Bluepri...
Benzinga Newsdesk
Needham Maintains Buy on Blueprint Medicines,...
Benzinga Newsdesk

Wednesday, October 30, 2024

Blueprint Medicines shares are trading higher...
Benzinga Newsdesk
Needham Reiterates Buy on Blueprint Medicines...
Benzinga Newsdesk
Blueprint Medicines Expects 2024 Ayvakit Net ...
Benzinga Newsdesk
Blueprint Medicines Q3 2024 GAAP EPS $(0.89) ...
Benzinga Newsdesk

Thursday, October 24, 2024

Analyst Ratings For Blueprint Medicines
Benzinga Insights
UBS Initiates Coverage On Blueprint Medicines...
Benzinga Newsdesk

Tuesday, August 13, 2024

9 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights

Thursday, August 08, 2024

10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights

Monday, August 05, 2024

Needham Maintains Buy on Blueprint Medicines,...
Benzinga Newsdesk

Friday, August 02, 2024

Guggenheim Maintains Buy on Blueprint Medicin...
Benzinga Newsdesk
Baird Maintains Outperform on Blueprint Medic...
Benzinga Newsdesk

Thursday, August 01, 2024

Needham Reiterates Buy on Blueprint Medicines...
Benzinga Newsdesk
Blueprint Medicines Continues To Expect That ...
Benzinga Newsdesk
Blueprint Medicines Corp Raised 2024 Global A...
Benzinga Newsdesk
Blueprint Medicines Q2 2024 GAAP EPS $(0.80) ...
Benzinga Newsdesk

Tuesday, July 30, 2024

10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights

Monday, July 29, 2024

15 Analysts Have This To Say About Blueprint Medicines
Benzinga Insights
Barclays Maintains Equal-Weight on Blueprint ...
Benzinga Newsdesk

Friday, July 12, 2024

Morgan Stanley Maintains Equal-Weight on Blue...
Benzinga Newsdesk

Monday, July 08, 2024

Oppenheimer Maintains Outperform on Blueprint...
Benzinga Newsdesk

Friday, June 28, 2024

Expert Ratings For Blueprint Medicines
Benzinga Insights
Needham Reiterates Buy on Blueprint Medicines...
Benzinga Newsdesk

Friday, June 07, 2024

Assessing Blueprint Medicines: Insights From 16 Financial Analysts
Benzinga Insights
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk

Friday, May 17, 2024

10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights

Tuesday, May 14, 2024

Unveiling 18 Analyst Insights On Blueprint Medicines
Benzinga Insights
Stephens & Co. Initiates Coverage On Blueprin...
Benzinga Newsdesk

Monday, May 06, 2024

Leerink Partners Upgrades Blueprint Medicines...
Benzinga Newsdesk
Goldman Sachs Maintains Buy on Blueprint Medi...
Benzinga Newsdesk

Friday, May 03, 2024

Citigroup Maintains Sell on Blueprint Medicin...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Blueprin...
Benzinga Newsdesk
JMP Securities Maintains Market Outperform on...
Benzinga Newsdesk
Barclays Maintains Equal-Weight on Blueprint ...
Benzinga Newsdesk
Piper Sandler Maintains Neutral on Blueprint ...
Benzinga Newsdesk
Needham Maintains Buy on Blueprint Medicines,...
Benzinga Newsdesk

Thursday, May 02, 2024

C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
Needham Reiterates Buy on Blueprint Medicines...
Benzinga Newsdesk
Blueprint Medicines shares are trading higher...
Benzinga Newsdesk

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved